A Phase 1 interventional study of CP-690,550 and CP-690,550 in Renal Impairment, sponsored by Pfizer. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-07.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.
Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 21st largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2003, is one of 23 in phase 1, and was the 17th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18–80 · Healthy volunteers
Pfizer · Sites in United States
Ages 18–90 · Healthy volunteers
By country, each count listing its studies:
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 1 · Phase 3 4 · Phase 4 8
First in 2002; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 30 across the 36 interventional studies, 59 across the 1 observational. Of the 34 that completed or were terminated, 15 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Renal Insufficiency by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07315360PfizerA Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function | 2027-03-13 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Renal Insufficiency by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to evaluate the pharmacokinetics of CP-690,550 in subjects with mild, moderate or severe renal impairment, who do not require hemodialysis, compared to healthy controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy volunteers
Drug: CP-690,550
patients with mild (\>50 and ≤80 mL/min) renal impairment
Drug: CP-690,550
patients with moderate (≥30 and ≤50 mL/min) renal impairment
Drug: CP-690,550
patients with severe (\<30 mL/min) renal impairment
Drug: CP-690,550
10 mg (2 x 5 mg tablets), single dose
10 mg (2 x 5 mg tablets), single dose
10 mg (2 x 5 mg tablets), single dose
10 mg (2 x 5 mg tablets), single dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: 0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose
Maximum Observed Plasma Concentration (Cmax)
Time frame: 0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose
Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose
Renal Clearance (CL R)
Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time.
Time frame: 0 (Pre-dose) to 12 hours post-dose, 12 to 24 hours post-dose
| Milestone | CP-690,550 (Normal Renal Function) | CP-690,550 (Mild Renal Insufficiency) | CP-690,550 (Moderate Renal Insufficiency) | CP-690,550 (Severe Renal Insufficiency) |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| nanogram*hour/milliliter (ng*hr/mL) | CP-690,550 (Normal Renal Function) | CP-690,550 (Mild Renal Insufficiency) | CP-690,550 (Moderate Renal Insufficiency) | CP-690,550 (Severe Renal Insufficiency) |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] | 268 ± 71.5 | 370 ± 109 | 396 ± 154 | 615 ± 214 |
| ng/mL | CP-690,550 (Normal Renal Function) | CP-690,550 (Mild Renal Insufficiency) | CP-690,550 (Moderate Renal Insufficiency) | CP-690,550 (Severe Renal Insufficiency) |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 94.2 ± 25.3 | 87.3 ± 23.2 | 104 ± 47.5 | 111 ± 28.6 |
| hours | CP-690,550 (Normal Renal Function) | CP-690,550 (Mild Renal Insufficiency) | CP-690,550 (Moderate Renal Insufficiency) | CP-690,550 (Severe Renal Insufficiency) |
|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 0.75 (0.50 to 1.50) | 1.00 (0.50 to 1.50) | 0.75 (0.50 to 2.00) | 0.75 (0.50 to 1.50) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hours | CP-690,550 (Normal Renal Function) | CP-690,550 (Mild Renal Insufficiency) | CP-690,550 (Moderate Renal Insufficiency) | CP-690,550 (Severe Renal Insufficiency) |
|---|---|---|---|---|
| Plasma Decay Half-Life (t1/2) | 2.37 ± 0.363 | 2.83 ± 0.857 | 2.88 ± 0.653 | 3.77 ± 0.480 |
Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time.
| mL/min | CP-690,550 (Normal Renal Function) | CP-690,550 (Mild Renal Insufficiency) | CP-690,550 (Moderate Renal Insufficiency) | CP-690,550 (Severe Renal Insufficiency) |
|---|---|---|---|---|
| Renal Clearance (CL R) | 113 ± 16.2 | 84.7 ± 28.7 | 27.4 ± 15.9 | 19.9 ± 7.52 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CP-690,550 (Normal Renal Function) | — | 0/6 (0%) | 0/6 (0%) |
| CP-690,550 (Mild Renal Insufficiency) | — | 0/6 (0%) | 0/6 (0%) |
| CP-690,550 (Moderate Renal Insufficiency) | — | 0/6 (0%) | 3/6 (50%) |
| CP-690,550 (Severe Renal Insufficiency) | — | 0/6 (0%) | 1/6 (16.7%) |
| Event | CP-690,550 (Normal Renal Function) | CP-690,550 (Mild Renal Insufficiency) | CP-690,550 (Moderate Renal Insufficiency) | CP-690,550 (Severe Renal Insufficiency) |
|---|---|---|---|---|
| Respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 2/6 | 0/6 |
| HypertensionCardiac disorders | 0/6 | 0/6 | 0/6 | 1/6 |
| Tooth disorderGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/6 |
| Age Continuous(years) | CP-690,550 (Normal Renal Function) | CP-690,550 (Mild Renal Insufficiency) | CP-690,550 (Moderate Renal Insufficiency) | CP-690,550 (Severe Renal Insufficiency) | Total |
|---|---|---|---|---|---|
| Mean | 50.8 ± 9.7 | 61.2 ± 2.8 | 53.5 ± 11.1 | 59.0 ± 14.6 | 56.1 ± 10.7 |
| Sex: Female, Male(Participants) | CP-690,550 (Normal Renal Function) | CP-690,550 (Mild Renal Insufficiency) | CP-690,550 (Moderate Renal Insufficiency) | CP-690,550 (Severe Renal Insufficiency) | Total |
|---|---|---|---|---|---|
| Female | 2 | 2 | 4 | 3 | 11 |
| Male | 4 | 4 | 2 | 3 | 13 |
The record gives a start of Oct 2003, a primary completion of Mar 2004 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 8 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib